0001104659-13-041506.txt : 20130514
0001104659-13-041506.hdr.sgml : 20130514
20130514172930
ACCESSION NUMBER: 0001104659-13-041506
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130514
FILED AS OF DATE: 20130514
DATE AS OF CHANGE: 20130514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nashat Amir
CENTRAL INDEX KEY: 0001575843
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35900
FILM NUMBER: 13842817
MAIL ADDRESS:
STREET 1: 10835 ROAD TO THE CURE
STREET 2: SUITE 205
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Receptos, Inc.
CENTRAL INDEX KEY: 0001463729
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10835 ROAD TO THE CURE
STREET 2: SUITE 205
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 652-5712
MAIL ADDRESS:
STREET 1: 10835 ROAD TO THE CURE
STREET 2: SUITE 205
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.)
DATE OF NAME CHANGE: 20090522
FORMER COMPANY:
FORMER CONFORMED NAME: Receptor Pharmaceuticals Inc.
DATE OF NAME CHANGE: 20090507
4
1
a4.xml
4
X0306
4
2013-05-14
0
0001463729
Receptos, Inc.
RCPT
0001575843
Nashat Amir
10835 ROAD TO THE CURE, SUITE 205
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2013-05-14
4
C
0
1035597
7.73
A
1035597
I
See Footnotes
Common Stock
2013-05-14
4
P
0
151343
14.00
A
1186940
I
See Footnotes
Series B Preferred Stock
7.73
2013-05-14
4
C
0
7766989
0
D
Common Stock
1035597
0
I
See Footnotes
Beneficial ownership consists of; (i) 142,764 shares of common stock held by Polaris Venture Partners VI, L.P. ("Polaris Ventures"); (ii) 8,579 shares of common stock held by Polaris Venture Partners Founders' Fund VI, L.P. ("Polaris Fund"); (iii) an aggregate of 976,897 shares of common stock issued upon conversion of shares of Series B preferred stock held by Polaris Ventures; and (iv) an aggregate of 58,700 shares of common stock issued upon conversion of Series B preferred stock held by Polaris Fund. The general partner of Polaris Ventures and Polaris Fund is Polaris Venture Management Co. VI, LLC ("Polaris Management"), and Polaris Management has sole voting and investment power over such shares. Polaris Management disclaims beneficial ownership of all such shares, except to the extent of any pecuniary interest therein. Dr. Nashat is one of six members of Polaris Management.
He has shared voting and investment power over such shares and may be deemed the indirect beneficial owner of such shares. Dr. Nashat disclaims beneficial ownership over such shares, except to the extent of any pecuniary interest therein. The members of North Star Venture Management 2010 LLC are also members of Polaris Management, and as members of the general partner, they may be deemed to share voting and investment power over such shares. The principles of North Star Venture Management 2010 LLC disclaim beneficial ownership of such shares, except to the extent of their proportionate pecuniary interest therein.
The Series A Preferred Stock converted upon the closing of the Issuer's initial public offering at a conversion ratio of 1 share of Common Stock for every 7.5 shares of Series A Preferred Stock, for no additional consideration.
/s/ Amir Nashat
2013-05-14